Saito Laboratory of Cell Technology, Yaita, Tochigi, 329-1571, Japan.
College of Engineering, Nihon University, Koriyama, Fukushima, 963-8642, Japan.
Cell Mol Life Sci. 2019 Jan;76(1):45-65. doi: 10.1007/s00018-018-2924-7. Epub 2018 Oct 3.
The ability to control the transition from an undifferentiated stem cell to a specific cell fate is one of the key techniques that are required for the application of interventional technologies to regenerative medicine and the treatment of tumors and metastases and of neurodegenerative diseases. Reprogramming technologies, which include somatic cell nuclear transfer, induced pluripotent stem cells, and the direct reprogramming of specific cell lineages, have the potential to alter cell plasticity in translational medicine for cancer treatment. The characterization of cancer stem cells (CSCs), the identification of oncogene and tumor suppressor genes for CSCs, and the epigenetic study of CSCs and their microenvironments are important topics. This review summarizes the application of cell reprogramming technologies to cancer modeling and treatment and discusses possible obstacles, such as genetic and epigenetic alterations in cancer cells, as well as the strategies that can be used to overcome these obstacles to cancer research.
从未分化的干细胞向特定细胞命运的转变的能力是介入技术在再生医学和肿瘤及转移瘤以及神经退行性疾病的治疗中的应用所需要的关键技术之一。重编程技术包括体细胞核转移、诱导多能干细胞和特定细胞谱系的直接重编程,有可能改变癌症治疗转化医学中的细胞可塑性。癌症干细胞(CSCs)的特征、CSCs 的癌基因和肿瘤抑制基因的鉴定以及 CSCs 及其微环境的表观遗传学研究是重要的课题。这篇综述总结了细胞重编程技术在癌症建模和治疗中的应用,并讨论了可能的障碍,如癌细胞中的遗传和表观遗传改变,以及可以用来克服这些障碍的策略,以促进癌症研究。